BRAND · HEALTHCARE ROBOTICS

Diligent Robotics

Diligent Robotics built the most commercially deployed hospital assistant robot in America — not a walking biped for your living room, but Moxi, a wheeled mobile manipulator that hauls meds and lab samples so nurses stay with patients. Real US hospital revenue; zero home availability.

By Editorial Team · Updated July 7, 2026 · 10 min read

2017

FOUNDED

Austin, Texas

HEADQUARTERS

Thomaz & Chu

FOUNDERS

Serve Robotics (Jan 2026)

COMPANY STATUS

1 (Moxi)

ACTIVE MODELS

US hospitals only

AVAILABLE IN

Last verified July 2026 against diligentrobots.com, Serve Robotics 8-K (Jan 27, 2026), Moxi 2.0 launch (Oct 2025), and hospital deployment disclosures.

OUR TAKE

The hospital robot company with a million deliveries — and a new parent in Serve Robotics

Diligent Robotics was founded in 2017 in Austin, Texas by Andrea Thomaz (CEO) and Vivian Chu (co-founder, now chief innovation officer) — social roboticists trained at MIT, Georgia Tech, and the University of Texas at Austin. The company's thesis was never general-purpose bipedal humanoids for homes; it was socially intelligent mobile manipulation robots that work alongside clinical staff in busy hospital corridors.

Moxi is Diligent's platform: a wheeled robot with an extendable arm, secure drawers, and an expressive face designed to navigate elevators, open doors, and deliver medications, lab samples, and supplies autonomously. As of early 2026, Diligent reported nearly 100 Moxi robots across 25+ US hospital facilities, with more than 1.25 million autonomous deliveries completed — one of the largest commercial deployments of mobile manipulation robots working alongside people. Customers include Northwestern Medicine, ChristianaCare, Rochester General Hospital, UTMB Health, Shannon Medical Center, Endeavor Health, and Novant Health.

The company raised over $100 million from investors including Tiger Global, Canaan, and True Ventures before a strategic exit. On January 20, 2026, Serve Robotics (Nasdaq: SERV) announced it would acquire Diligent for $29 million in stock plus up to $5.3 million in earn-out milestones; the deal closed January 27, 2026 per SEC filings, with Diligent continuing as a subsidiary under Thomaz's leadership. Serve framed the acquisition as expanding its Physical AI platform from sidewalk delivery robots into indoor healthcare environments.

In October 2025, Diligent unveiled Moxi 2.0 at NVIDIA GTC — a next-generation platform with NVIDIA Thor compute (roughly 10× prior processing power), redesigned drawers and hardware based on nurse feedback, and a robot foundation model trained on years of hospital interaction data. First Moxi 2.0 units were planned for hospital deployment in the first half of 2026, with Diligent targeting 15+ robots per site and thousands deployed by 2030. Serve also disclosed expected annual revenue of $200,000–$400,000 per hospital facility.

For a robixone buyer evaluating Diligent: this is not a household humanoid. Moxi is sold through hospital RaaS (robot-as-a-service) contracts in the United States — pricing is not publicly disclosed for consumer purchase because there is no consumer product. Robixone rates Moxi at HOSI 8.5 for its category-leading hospital reliability, but its home suitability score reflects reality: Moxi belongs in a health system, not a UK or US apartment.

THE LINEUP

Every model Diligent Robotics currently makes

A summary of each Diligent Robotics robot we cover, with our pick for most households.

Diligent Moxi

Diligent Robotics Moxi stands out as the only healthcare-centric humanoid platform in the world, an Austin-based platform company purpose-built to work in hospital workflows. It’s earned real production time in named hospital partners across the US, giving it genuine healthcare-deployment field time that no other humanoid platform can convincingly assert. We test whether Diligent’s healthcare-first orientation builds a humanoid worth considering.

HOSI 8.5 / 10 overall

Read full Diligent Moxi review →

REAL OWNER SENTIMENT

What owners say about Diligent Robotics

Moxi sentiment comes from US hospital executives and nursing leadership — not household owners. Praise centers on returned clinical hours and staff morale; skepticism focuses on acquisition uncertainty and whether hospital RaaS economics scale beyond early adopters.

REDDIT Feb 2026

u/hospital_ops

“Moxi isn't a humanoid you buy — it's a hospital logistics contract. But among deployed healthcare robots, Diligent actually has the fleet hours and nurse testimonials to back the hype.”

DEPLOYMENT REALITY

REDDIT Jan 2026

u/serve_merger_watch

“Serve buying Diligent for $29M stock after $100M+ raised is a sobering exit — but Moxi keeps operating and Thomaz stays CEO. The question is whether sidewalk-delivery autonomy translates to hospital workflows.”

ACQUISITION

YOUTUBE Nov 2025

@clinical_automation

“The social face isn't gimmickry — nurses actually engage with Moxi. Reliability in live hospital fleets is what separates Diligent from demo-stage humanoid startups.”

CLINICAL TRUST

WILL THE COMPANY BE AROUND IN 5 YEARS?

Diligent Robotics business stability

Diligent Robotics is among the most commercially proven service-robotics companies in US healthcare — a rare profile in a sector dominated by pilot announcements. More than 1.25 million autonomous hospital deliveries, 25+ live facilities, and named health-system customers give Moxi real operational credibility that most humanoid brands lack.

The January 2026 Serve Robotics acquisition changes the ownership story but not the immediate product footprint. Diligent continues as a subsidiary led by Andrea Thomaz; Serve brings public-market capital, a shared autonomy stack, and a path to scale Moxi 2.0 rollouts. The $29 million headline valuation reflects a strategic tuck-in after prior venture rounds exceeding $100 million — buyers should read that as consolidation, not collapse.

Leadership depth remains a strength. Thomaz is a recognized social-robotics researcher; Chu drives Moxi 2.0 hardware and foundation-model strategy. NVIDIA partnership (Jetson, Omniverse, Thor on Moxi 2.0) provides compute and ecosystem backing. The main risk for hospital customers is integration execution under Serve — not whether Moxi works in hospitals today.

Quick risk summary

Commercial proof

1.25M+ deliveries; ~100 robots; 25+ US hospitals; named health-system customers.

Healthcare specialization

Purpose-built for hospital workflows; HIPAA-aware deployments; HOSI 8.5 reliability score.

Post-acquisition path

Acquired by Serve Robotics (Jan 2026); integration and scaling under new parent still unfolding.

HOW DILIGENT ROBOTICS HANDLES YOUR DATA

Diligent Robotics privacy and data approach

Moxi operates in US hospitals with cameras, lidar, and connectivity for autonomous navigation through patient-care areas, nurses' stations, and clinical corridors. Deployments run under hospital enterprise contracts with HIPAA-aware data governance — not consumer terms of service.

Diligent's Moxi 2.0 platform collects large-scale human-robot interaction data from live fleets to train navigation and manipulation foundation models. What stays on-robot versus what feeds cloud training depends on each health system's contract and configuration.

For US or UK household buyers, Diligent is irrelevant as a privacy evaluation — Moxi is not sold to consumers. Privacy questions matter for hospital procurement teams assessing camera coverage, data retention, and patient-area navigation policies.

WHEN SOMETHING GOES WRONG

Where you can get a Diligent Robotics serviced

Diligent Robotics supports Moxi through its Austin headquarters and dedicated hospital customer-success teams across deployed US health systems. Service is bundled into enterprise RaaS contracts — there is no consumer purchase path, and no UK hospital fleet as of mid-2026.

Country	Location	Contact
United States	Austin, TX (HQ)	https://www.diligentrobots.com/
United States	25+ hospital deployments	https://www.diligentrobots.com/

QUESTIONS

Frequently asked questions about Diligent Robotics

Is Diligent Robotics a real company?

Yes. Diligent Robotics was founded in 2017 in Austin, Texas by Andrea Thomaz and Vivian Chu. It deploys Moxi hospital assistant robots across 25+ US health systems and was acquired by Serve Robotics in January 2026, continuing as a subsidiary under Thomaz.

What is the Diligent Moxi robot?

Moxi is a socially intelligent mobile manipulation robot — wheeled base, extendable arm, secure drawers — that autonomously delivers medications, lab samples, and supplies in US hospitals. It is not a bipedal home humanoid.

Can I buy a Moxi for home use?

No. Moxi is sold through hospital robot-as-a-service contracts in the United States. There is no consumer pricing or residential availability on robixone or from Diligent directly.

What happened to Diligent Robotics in 2026?

Serve Robotics acquired Diligent in January 2026 for $29 million in stock (plus up to $5.3 million earn-out). The deal closed January 27, 2026. Diligent continues operating Moxi as a Serve subsidiary led by CEO Andrea Thomaz.

What is Moxi 2.0?

Moxi 2.0 is Diligent's next-generation platform unveiled October 2025 at NVIDIA GTC, featuring NVIDIA Thor compute, redesigned hardware, and a robot foundation model trained on 1.25M+ real hospital deliveries. First units were planned for hospital rollout in H1 2026.

Is Diligent Moxi available in the UK?

No. As of mid-2026, Moxi deployments are US hospital facilities only. UK household buyers should not expect availability — this is an enterprise healthcare platform, not a residential robot.